|
|
Article: PathoGenesis Initiates Phase II Clinical Trial in Tuberculosis Patients
- Article from:
- PR Newswire
- Article date:
- October 10, 1997
CopyrightCOPYRIGHT 1997 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE, Oct. 10 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) announced today that it has initiated an open-label Phase II clinical trial at San Francisco General Hospital. The study will test TOBI(TM) (tobramycin solution for inhalation) in patients with contagious pulmonary tuberculosis.
The company plans to enroll 15-20 patients age 18 or older who have been newly diagnosed with pulmonary tuberculosis. During the eight-day open-label trial, patients will receive 300 mg. of TOBI twice daily for five consecutive days using a nebulizer. If successful, TOBI will decrease bacterial counts in the sputum (phlegm) more rapidly than standard systemic ...